Note 15 - Income Taxes	9 Months Ended
Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	15. INCOME TAXES The Company is subject to taxation in the U.S., as well as various state and foreign jurisdictions. The Company continues to record a full valuation allowance against the Company’s U.S. net deferred tax assets as it is not more likely than not that the Company will realize a benefit from these assets in a future period. During the nine months ended September 30, 2018, the Company recorded a valuation allowance of $0.6 million against the Company's foreign UK net deferred tax assets as it is not more likely than not that the Company will realize a benefit from those assets in a future period. In future periods, tax benefits and related deferred tax assets will be recognized when management concludes realization of such amounts is more likely than not. A net income tax benefit of $143 thousand and $280 thousand was recorded to the income tax provision for the three and nine months ended September 30, 2018, respectively, resulting in an effective tax rate of 8.5% and 2.8%, respectively. The income tax benefit for the three and nine months ended September 30, 2018 includes realizable benefits on losses in certain foreign jurisdictions offset by taxes on profitable foreign operations, domestic state minimum taxes and a valuation allowance on the net deferred tax assets of the foreign UK operations. During the three months ended September 30, 2018 the Company received notice that the Canada Revenue Agency had accepted the Company’s applications for a Scientific Research and Experimental Development (SRED) tax credit for research and development performed in Canada for a prior year. Accordingly, for the three and nine months ended September 30, 2018, the Company recorded a tax benefit of $206 thousand related to the SRED credit. Starting with the third quarter 2018 tax provision, current year estimated SRED credits of approximately $37 thousand are included as part of the Company's normal quarterly tax provision calculation and are included in the total shown above. All of our USA and the foreign UK net deferred tax assets were reduced by a valuation allowance. The Company’s total income tax benefit and effective tax rate for the three and nine months ended September 30, 2017 was $177 thousand and $560 thousand, respectively resulting in an effective tax rate of 8.5% and 7.1%, respectively. The income tax benefit for the three months and nine months ended September 30, 2017 related to realizable benefits on losses in certain foreign jurisdictions offset by taxes on profitable foreign operations and domestic state minimum taxes. During the three months ended September 30, 2017 the Company recorded a tax benefit of $51 thousand related to the SRED credit. All of our USA deferred tax assets were reduced by a valuation allowance.

15.

INCOME TAXES

The Company is subject to taxation in the U.S., as well as various state and foreign jurisdictions. The Company continues to record a full valuation allowance against the Company’s U.S. net deferred tax assets as it is

not

more likely than

not

that the Company will realize a benefit from these assets in a future period. During the

nine

months ended

September 30, 2018,

the Company recorded a valuation allowance of

$0.6

million against the Company's foreign UK net deferred tax assets as it is

not

more likely than

not

that the Company will realize a benefit from those assets in a future period. In future periods, tax benefits and related deferred tax assets will be recognized when management concludes realization of such amounts is more likely than

not.

A net income tax benefit of

$143

thousand and

$280

thousand was recorded to the income tax provision for the

three

and

nine

months ended

September

30,

2018,

respectively, resulting in an effective tax rate of

8.5%

and

2.8%,

respectively. The income tax benefit for the

three

and

nine

months ended

September

30,

2018

includes realizable benefits on losses in certain foreign jurisdictions offset by taxes on profitable foreign operations, domestic state minimum taxes and a valuation allowance on the net deferred tax assets of the foreign UK operations. During the

three

months ended

September 30, 2018

the Company received notice that the Canada Revenue Agency had accepted the Company’s applications for a Scientific Research and Experimental Development (SRED) tax credit for research and development performed in Canada for a prior year. Accordingly, for the

three

and

nine

months ended

September 30, 2018,

the Company recorded a tax benefit of

$206

thousand related to the SRED credit. Starting with the

third

quarter

2018

tax provision, current year estimated SRED credits of approximately

$37

thousand are included as part of the Company's normal quarterly tax provision calculation and are included in the total shown above. All of our USA and the foreign UK net deferred tax assets were reduced by a valuation allowance.

The Company’s total income tax benefit and effective tax rate for the

three

and

nine

months ended

September

30,

2017

was

$177

thousand and

$560

thousand, respectively resulting in an effective tax rate of

8.5%

and

7.1%,

respectively. The income tax benefit for the

three

months and

nine

months ended

September

30,

2017

related to realizable benefits on losses in certain foreign jurisdictions offset by taxes on profitable foreign operations and domestic state minimum taxes. During the

three

months ended

September 30, 2017

the Company recorded a tax benefit of

$51

thousand related to the SRED credit. All of our USA deferred tax assets were reduced by a valuation allowance.